Table 1.
Demographic data
| Total | First period | Second period | Third period | |
|---|---|---|---|---|
| 05/2018–10/2018 | 11/2018–04/2019 | 05/2019–10/2019 | ||
| n = 225 | n = 60 | n = 87 | n = 78 | |
| Sex | ||||
| Female | 28 (12.4%) | 4 (6.7%) | 9 (10.3%) | 15 (19.2%) |
| Male | 197 (87.6%) | 56 (93.3%) | 78 (89.7%) | 63 (80.8%) |
| Age in years, mean (range) | 58.7 (19–95) | 58.0 (19–85) | 59.4 (24–85) | 58.6 (23–95) |
| BMI (kg/m2), mean (range) | 25.5 (16.3–42.6) | 25.6 (17.9–34.6) | 25.4 (16.3–34.3) | 25.5 (17.0–42.6) |
| Ethnicity | ||||
| Central European | 169 (75.1%) | 44 (73.3%) | 67 (77.0%) | 58 (74.4%) |
| Mediterranean | 56 (24.9%) | 16 (26.7%) | 20 (23.0%) | 20 (25.6%) |
| ASA Classification | ||||
| 1 | 51 (22.7%) | 12 (20.0%) | 16 (18.4%) | 23 (29.5%) |
| 2 | 144 (64.0%) | 35 (58.3%) | 63 (72.4%) | 46 (59.0%) |
| 3 | 20 (8.9%) | 5 (8.3%) | 7 (8.0%) | 8 (10.3%) |
| Unknown | 10 (4.4%) | 8 (13.3%) | 1 (1.1%) | 1 (1.3%) |
| Comorbidities | ||||
| Arterial hypertension | 87 (38.7%) | 23 (38.3%) | 37 (42.5%) | 27 (34.6%) |
| Diabetes mellitus | 19 (5.8%) | 7 (11.7%) | 7 (8.0%) | 5 (6.4%) |
| COPD | 7 (3.1%) | 2 (3.3%) | 3 (3.4%) | 2 (2.6%) |
| Coronary heart disease | 16 (7.1%) | 5 (8.3%) | 4 (4.6%) | 7 (9.0%) |
| Nicotine abuse | 67 (29.8%) | 22 (36.7%) | 26 (29.9%) | 19 (24.4%) |
| Oral anticoagulant | 8 (3.6%) | 2 (3.3%) | 3 (3.4%) | 3 (3.8%) |
| Aspirin/Clopidogrel | 30 (13.3%) | 11 (18.3%) | 12 (13.8%) | 7 (9.0%) |
BMI Body mass index, COPD chronic obstructive pulmonary disease, ASA American Society of Anesthesiologists